Abilify in adolescents

Use of Abilify (aripiprazole) in adolescents aged 15 years and above with schizophrenia has been approved. The recommended dose in this population is 10mg daily. Use of the drug to treat manic episodes in bipolar disorder remains not recommended under 18 years.

View Abilify drug record

Further information: Otsuka


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Skin cancer warning for actinic keratosis treatment

Skin cancer warning for actinic keratosis treatment

Patients treated with ingenol mebutate (Picato) should...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: Accupro, Dermovate, Norinyl-1.
Use our...

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.